Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Skrabl-Baumgartner, A; Erwa, W; Muntean, W; Jahnel, J.
Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.
Scand J Rheumatol. 2015; 44(5):359-362
Doi: 10.3109/03009742.2015.1022213
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Jahnel Jörg
- Skrabl-Baumgartner Andrea
- Co-Autor*innen der Med Uni Graz
- Erwa Wolfgang
- Muntean Eugen
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA). AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA. Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower. The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adalimumab - blood
- Adalimumab - immunology
- Adalimumab - therapeutic use
- Adolescent -
- Antibodies, Anti-Idiotypic - blood
- Antibodies, Anti-Idiotypic - immunology
- Antirheumatic Agents - blood
- Antirheumatic Agents - immunology
- Antirheumatic Agents - therapeutic use
- Arthritis, Juvenile - blood
- Arthritis, Juvenile - drug therapy
- Arthritis, Juvenile - immunology
- Biomarkers - blood
- Child -
- Drug Therapy, Combination -
- Female -
- Humans -
- Male -
- Methotrexate - therapeutic use
- Severity of Illness Index -
- Treatment Failure -
- Treatment Outcome -
- Tumor Necrosis Factor-alpha - antagonists & inhibitors